Base de dados : LILACS
Pesquisa : E02.095.301 [Categoria DeCS]
Referências encontradas : 201 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 21 ir para página                         

  1 / 201 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-729292
Autor: Gowdak, Luís Henrique Wolff.
Título: Perspectivas no tratamento da doença arterial coronária / Treatment perspectives for coronary artery disease
Fonte: Rev. Soc. Cardiol. Estado de Säo Paulo;24(1):42-48, jan.-mar. 2014. ilus.
Idioma: pt.
Resumo: A despeito dos incontestáveis avanços no tratamento médico e em procedimentos de revascularização miocárdica (percutâneous e cirúrgicos), sintomas debilitantes relacionados à doença arterial coronária podem ocorrer devido à progressão da doença com envolvimento difuso arterial e oclusão de enxertos prévios ou reestenose pós-angioplastia, impossibilitando novos procedimentos de revascularização miocárdica. Característica desta condição (angina refratária) é o grande prejuízo dos afetados em termos de qualidade de vida, impedidos de realizar as atividades mais triviais do dia-a-dia (caminhar poucos metros no plano ou mesmo banha-se) sem que a dor anginosa ocorra; alguns pacientes são despertados frequentemente durante a noite por angina. Assim, para estes pacientes, o objetivo principal do tratamento é a melhoria na qualidade de vida, com maior tolerância ao esforço, e menor necessidade de hospitalizações e procedimentos diagnósticos ou terapêuticos. Neste contexto, elencaremos sucintamente as principais estratégias terapêuticas não farmacológica em desenvolvimento para o tratamento de pacientes com angina refratária, incluindo terapia gênica, terapia celular, revascularização transmiocárdica a laser, contrapulsação externa, estimulação de medula espinhal e revascularização miocárdica extracorpórea por ondas de choque.

Despite great advances in both medical management and myocardial revascularization procedures (percutaneous and surgical), disabling symptoms due to coronary artery disease may occur due to progression of the beds, grafts failures after successful bypass surgery, and/or stent restenosis, preventing further revacularization attempts. Patients with refractory angina have a mared impairment in quality of life, unable to perform any daily avtivity such as slowl walking or even taking a bath without chest pain; many patients are awaken during their sleep due to chest disconfort. For theses patients, the main objective f treatment is to improve their quality of life, with better exercise tolerance, and decreased number of hospitalizations and/or diagnosis/therapeutic procedures. In this paper, we briefly discuss new non-pharmacological therapeutic strategies being developed for patients with adavanced CAD including gene therapy, cell therapy, transmyocardial laser revascularization, enhanced external conter-pulsation, spinal cord stimulation and extracorporeal shockwave myocardial revascularization.
Descritores: Angina Pectoris/terapia
Doença da Artéria Coronariana/terapia
Doenças Cardiovasculares/mortalidade
Revascularização Miocárdica/tendências
-Fatores de Risco
Neuroestimuladores Implantáveis
Terapia Baseada em Transplante de Células e Tecidos/tendências
Terapia Genética/métodos
Limites: Humanos
Masculino
Feminino
Tipo de Publ: Estudo Comparativo
Responsável: BR44.1 - Serviço de Biblioteca, Documentação Científica e Didática Prof. Dr. Luiz Venere Décourt


  2 / 201 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-741450
Autor: Anon.
Título: An interview with Eiji Tanaka
Fonte: Dental press j. orthod. (Impr.);20(1):30-39, Jan-Feb/2015. graf.
Idioma: en.
Descritores: Ortodontia/tendências
-Aparelhos Ortodônticos/efeitos adversos
Ortodontia/economia
Apoio à Pesquisa como Assunto
Reabsorção da Raiz/prevenção & controle
Terapia por Ultrassom/métodos
Imageamento por Ressonância Magnética/métodos
Terapia Genética/métodos
Transtornos da Articulação Temporomandibular/diagnóstico
Transtornos da Articulação Temporomandibular/genética
Transtornos da Articulação Temporomandibular/terapia
Pesquisa em Odontologia/economia
Pesquisa em Odontologia/tendências
Transtornos Musculares Atróficos/terapia
Tomografia Computadorizada de Feixe Cônico/métodos
Financiamento Governamental
Organização do Financiamento
Ondas Ultrassônicas
Japão
Limites: Humanos
Tipo de Publ: Entrevista
Responsável: BR1.1 - BIREME


  3 / 201 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-639878 LILACS-Express
Autor: OSORIO, JOSÉ HENRY.
Título: Cuestionamiento éticos relacionados con la terapia génica para el tratamiento de enfermedades hereditarias / Ethial questioniing related to gene theraphy for inherited diseases treatment
Fonte: Rev. luna azul;(32):114-120, ene.-jun. 2011.
Idioma: es.
Resumo: La introducción de secuencias genéticas exógenas denominadas transgenes se denomina terapia génica, y tiene el propósito de corregir alteraciones genotípicas o fenotípicas en el organismo humano. Esta terapia puede realizarse en células somáticas o en células germinales; los cuestionamientos éticos relacionados con la terapia génica somática tienen que ver básicamente con los riesgos potenciales para la salud y el consentimiento informado, mientras que la terapia génica en células germinales tiene el potencial de afectar permanentemente a futuras generaciones de personas. Debido a que la terapia génica involucra mucho más que la simple alteración de las secuencias genéticas, esta revisión presenta los principales problemas éticos asociados con la terapia génica para enfermedades hereditarias.

The introduction of exogenous genetic sequences named transgenes is known as gene therapy and has the purpose of correcting genotypic and phenotypic alterations in the human organism. This therapy can be carried out in somatic cells or in germinal cells. The ethical questioning related to somatic gene therapy has to do basically with the potential risks for health and the informed consent while germ-line gene therapy has the potential to affect permanently future generations. Since genic therapy involves much more than the simple alteration of genetic sequences, this revision presents the main ethical problems associated with gene therapy for inherited disease.
Descritores: Terapia Genética
-Terapêutica
Células Germinativas
Doenças Genéticas Inatas
Limites: Humanos
Tipo de Publ: Artigo Clássico
Responsável: CO54.1 - Centro de Biblioteca e Información Científica


  4 / 201 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-892932
Autor: Ergün, Osman; Koşar, Pinar Aslan; Onaran, İbrahim; Darici, Hakan; Koşar, Alim.
Título: Lysozyme gene treatment in testosterone induced benign prostate hyperplasia rat model and comparasion of its' effectiveness with botulinum toxin injection
Fonte: Int. braz. j. urol;43(6):1167-1175, Nov.-Dec. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objectives: To compare the effects and histopathological changes of botulinum neurotoxin type A and lysozyme gene injections into prostate tissue within a testosterone induced benign prostate hyperplasia rat model. Materials and Methods: 40 male Wistar rats were randomized into four Groups. Group-1: Control, Group-2: Testosterone replacement, Group-3: Testosterone+botulinum neurotoxin type A, Group-4: Testosterone+plazmid DNA/liposome complex. Results: Estimated prostate volume of the testosterone injected Groups were higher than the control (p <0.05). Actual prostate weight of the testosterone injected Groups was higher than the control Group (p <0.05). Testosterone undecanoate increased the prostate weight by 39%. Botulinum neurotoxin type A treatment led to an estimated prostate volume and actual prostate weights decreased up to 32.5% in rats leading to prostate apoptosis. Lysozyme gene treatment led to an estimated prostate volume and actual prostate weights decrease up to 38.7%. Conclusion: Lysozyme gene and botulinum neurotoxin type A treatments for prostate volume decreasing effect have been verified in the present study that could be anew modality of treatment in prostatic benign hyperplasia that needs to be verified in large randomized human experimental studies.
Descritores: Hiperplasia Prostática/tratamento farmacológico
Terapia Genética/métodos
Muramidase/genética
Toxinas Botulínicas Tipo A/uso terapêutico
-Hiperplasia Prostática/induzido quimicamente
Testosterona
Ratos Wistar
Modelos Animais de Doenças
Limites: Animais
Masculino
Ratos
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME


  5 / 201 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-952824
Autor: Barros, Luciana; Pretti, Marco Antonio; Chicaybam, Leonardo; Abdo, Luiza; Boroni, Mariana; Bonamino, Martin Hernán.
Título: Immunological-based approaches for cancer therapy
Fonte: Clinics;73(supl.1):e429s, 2018. graf.
Idioma: en.
Resumo: The immunologic landscape of tumors has been continuously unveiled, providing a new look at the interactions between cancer cells and the immune system. Emerging tumor cells are constantly eliminated by the immune system, but some cells establish a long-term equilibrium phase leading to tumor immunoediting and, eventually, evasion. During this process, tumor cells tend to acquire more mutations. Bearing a high mutation burden leads to a greater number of neoantigens with the potential to initiate an immune response. Although many tumors evoke an immune response, tumor clearance by the immune system does not occur due to a suppressive tumor microenvironment. The mechanisms by which tumors achieve the ability to evade immunologic control vary. Understanding these differences is crucial for the improvement and application of new immune-based therapies. Much effort has been placed in developing in silico algorithms to predict tumor immunogenicity and to characterize the microenvironment via high-throughput sequencing and gene expression techniques. Each sequencing source, transcriptomics, and genomics yields a distinct level of data, helping to elucidate the tumor-based immune responses and guiding the fine-tuning of current and upcoming immune-based therapies. In this review, we explore some of the immunological concepts behind the new immunotherapies and the bioinformatic tools to study the immunological aspects of tumors, focusing on neoantigen determination and microenvironment deconvolution. We further discuss the immune-based therapies already in clinical use, those underway for future clinical application, the next steps in immunotherapy, and how the characterization of the tumor immune contexture can impact therapies aiming to promote or unleash immune-based tumor elimination.
Descritores: Imunoterapia/métodos
Neoplasias/imunologia
Neoplasias/terapia
-Terapia Genética
Transformação Celular Neoplásica
Terapia Combinada
Evasão Tumoral/imunologia
Vacinas Anticâncer/uso terapêutico
Microambiente Tumoral/imunologia
Mutação
Antígenos de Neoplasias/análise
Neoplasias/genética
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  6 / 201 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-952830
Autor: Strauss, Bryan E; Silva, Gissele Rolemberg Oliveira; de Luna Vieira, Igor; Cerqueira, Otto Luiz Dutra; Del Valle, Paulo Roberto; Medrano, Ruan Felipe Vieira; Mendonça, Samir Andrade.
Título: Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer
Fonte: Clinics;73(supl.1):e479s, 2018. graf.
Idioma: en.
Projeto: IVL; . MGL; . PRDV; . RFVM; . BES.
Resumo: While cancer immunotherapy has gained much deserved attention in recent years, many areas regarding the optimization of such modalities remain unexplored, including the development of novel approaches and the strategic combination of therapies that target multiple aspects of the cancer-immunity cycle. Our own work involves the use of gene transfer technology to promote cell death and immune stimulation. Such immunogenic cell death, mediated by the combined transfer of the alternate reading frame (p14ARF in humans and p19Arf in mice) and the interferon-β cDNA in our case, was shown to promote an antitumor immune response in mouse models of melanoma and lung carcinoma. With these encouraging results, we are now setting out on the road toward translational and preclinical development of our novel immunotherapeutic approach. Here, we outline the perspectives and challenges that we face, including the use of human tumor and immune cells to verify the response seen in mouse models and the incorporation of clinically relevant models, such as patient-derived xenografts and spontaneous tumors in animals. In addition, we seek to combine our immunotherapeutic approach with other treatments, such as chemotherapy or checkpoint blockade, with the goal of reducing dosage and increasing efficacy. The success of any translational research requires the cooperation of a multidisciplinary team of professionals involved in laboratory and clinical research, a relationship that is fostered at the Cancer Institute of Sao Paulo.
Descritores: Terapia Genética/métodos
Fases de Leitura/genética
Interferon beta/uso terapêutico
Técnicas de Transferência de Genes
Imunoterapia/métodos
Neoplasias/terapia
-Morte Celular/genética
Inibidor p16 de Quinase Dependente de Ciclina/genética
Proteína Supressora de Tumor p14ARF/genética
Neoplasias/imunologia
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  7 / 201 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-952839
Autor: Tamura, Rodrigo Esaki; de Luna, Igor Vieira; Lana, Marlous Gomes; Strauss, Bryan E.
Título: Improving adenoviral vectors and strategies for prostate cancer gene therapy
Fonte: Clinics;73(supl.1):e476s, 2018. graf.
Idioma: en.
Resumo: Gene therapy has been evaluated for the treatment of prostate cancer and includes the application of adenoviral vectors encoding a suicide gene or oncolytic adenoviruses that may be armed with a functional transgene. In parallel, versions of adenoviral vector expressing the p53 gene (Ad-p53) have been tested as treatments for head and neck squamous cell carcinoma and non-small cell lung cancer. Although Ad-p53 gene therapy has yielded some interesting results when applied to prostate cancer, it has not been widely explored, perhaps due to current limitations of the approach. To achieve better functionality, improvements in the gene transfer system and the therapeutic regimen may be required. We have developed adenoviral vectors whose transgene expression is controlled by a p53-responsive promoter, which creates a positive feedback mechanism when used to drive the expression of p53. Together with improvements that permit efficient transduction, this new approach was more effective than the use of traditional versions of Ad-p53 in killing prostate cancer cell lines and inhibiting tumor progression. Even so, gene therapy is not expected to replace traditional chemotherapy but should complement the standard of care. In fact, chemotherapy has been shown to assist in viral transduction and transgene expression. The cooperation between gene therapy and chemotherapy is expected to effectively kill tumor cells while permitting the use of reduced chemotherapy drug concentrations and, thus, lowering side effects. Therefore, the combination of gene therapy and chemotherapy may prove essential for the success of both approaches.
Descritores: Neoplasias da Próstata/terapia
Terapia Genética/métodos
Adenoviridae/genética
Carcinoma Pulmonar de Células não Pequenas/genética
Vetores Genéticos/uso terapêutico
Neoplasias Pulmonares/genética
-Neoplasias da Próstata/genética
Neoplasias da Próstata/imunologia
Proteína Supressora de Tumor p53/biossíntese
Antígeno Prostático Específico/genética
Genes Transgênicos Suicidas
Proteínas de Neoplasias/genética
Limites: Humanos
Masculino
Tipo de Publ: Research Support, Non-U.S. Gov't
Revisão
Responsável: BR1.1 - BIREME


  8 / 201 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1248965
Autor: Antunes-Foschini, Rosalia; Adriano, Leidiane; Murashima, Adriana de Andrade Batista; Barbosa, Amanda Pires; Nominato, Luis Fernando; Dias, Lara Cristina; Fantucci, Marina Zilio; Garcia, Denny Marcos; Alves, Monica; Rocha, Eduardo Melani.
Título: Limitations and advances in new treatments and future perspectives of corneal blindness / Limitações e avanços em novos tratamentos e perspectivas futuras na cegueira corneal
Fonte: Arq. bras. oftalmol;84(3):282-296, May-June 2021. tab, graf.
Idioma: en.
Projeto: Fundação de Amparo a Pesquisa do Estado de São Paulo; . Conselho Nacional de Desenvolvimento Científico e Tecnológico; . University of São Paulo.
Resumo: ABSTRACT This review is intended to describe the therapeutic approaches for corneal blindness, detailing the steps and elements involved in corneal wound healing. It also presents the limitations of the actual surgical and pharmacological strategies used to restore and maintain corneal transparency in terms of long-term survival and geographic coverage. In addition, we critically review the perspectives of anabolic agents, including vitamin A, hormones, growth factors, and novel promitotic and anti-inflammatory modulators, to assist corneal wound healing. We discuss the studies involving nanotechnology, gene therapy, and tissue reengineering as potential future strategies to work solely or in combination with corneal surgery to prevent or revert corneal blindness.(AU)

RESUMO O presente trabalho traz uma revisão das abordagens terapêuticas para a cegueira da córnea. O estudo detalha as etapas e os elementos envolvidos na cicatrização da córnea. Ele mostra as limitações das estratégias cirúrgicas e farmacológicas usadas para restaurar e manter a transparência da córnea em termos de sobrevida a longo prazo e alcance geográfico. As perspectivas dos agentes anabólicos, incluindo vitamina A, hormônios, fatores de crescimento e novos moduladores pró-mitóticos e anti-inflamatórios para auxiliar a cicatrização da ferida na córnea, são revisadas criticamente. Aqui, apresentamos estudos envolvendo nanotecnologia, terapia gênica e reengenharia de tecidos como possíveis estratégias futuras para atuar de maneira isolada ou combinada com a cirurgia da córnea para prevenir ou reverter a cegueira corneana.(AU)
Descritores: Cegueira/prevenção & controle
Cegueira/terapia
Lesões da Córnea/prevenção & controle
Lesões da Córnea/terapia
-Células-Tronco
Vitamina A/uso terapêutico
Terapia Genética/instrumentação
Nanotecnologia/instrumentação
Peptídeos e Proteínas de Sinalização Intercelular/uso terapêutico
Hormônios/uso terapêutico
Anti-Inflamatórios/uso terapêutico
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  9 / 201 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1089607
Autor: Zhang, Jianfeng; Hu, Guojin; Yang, Shengyong.
Título: Intracoronary sarcoplasmic reticulum calcium-atpase gene therapy in advanced heart failure patients with reduced ejection fraction: a prospective cohort study
Fonte: Clinics;75:e1530, 2020. tab, graf.
Idioma: en.
Resumo: OBJECTIVE: Heart failure is a progressive and debilitating disease. Intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy may improve the function of cardiac muscle cells. This study aimed to test the hypothesis that intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy can improve outcomes and reduce the number of recurrent and terminal events in advanced heart failure patients with reduced ejection fraction. METHODS: A total of 768 heart failure patients with reduced ejection fraction and New York Heart Association classification II to IV were included in this prospective cohort study. Patients either underwent intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy (CA group, n=384) or received oral placebo (PA group; n=384). Data regarding recurrent and terminal event(s), treatment-emergent adverse effects, and outcome measures were collected and analyzed. RESULTS: After a follow-up period of 18 months, intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy reduced the number of hospital admissions (p=0.001), ambulatory treatments (p=0.0004), and deaths (p=0.024). Additionally, intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy improved the left ventricular ejection fraction (p<0.0001) and Kansas City Cardiomyopathy Questionnaire score (p<0.0001). The number of recurrent and terminal events/patients were higher in the PA group than in the CA group after the follow-up period of 18 months (p=0.015). The effect of the intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy was independent of the confounding variables. No new arrhythmias were reported in the CA group. CONCLUSIONS: Intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy reduces the number of recurrent and terminal events and improves the clinical course of advanced heart failure patients with reduced ejection fraction.
Descritores: Retículo Sarcoplasmático
Insuficiência Cardíaca
-Volume Sistólico
Terapia Genética
Cálcio
Estudos Prospectivos
Função Ventricular Esquerda
ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático
Limites: Humanos
Masculino
Feminino
Responsável: BR1.1 - BIREME


  10 / 201 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-365254
Autor: Fett-Conte, Agnes C; Salles, Andréa B. C. F.
Título: A importância do gene p53 na carcinogênese humana / The importance of the p53 gene in human carcinogenesis
Fonte: Rev. bras. hematol. hemoter;24(2):85-89, abr.-jun. 2002.
Idioma: pt.
Resumo: Existem várias razões que justificam o título de "guardião do genoma" do gene P53. Seu envolvimento, direto ou indireto, tem sido observado na etiopatogenia de praticamente todas as neoplasias humanas, incluindo as leucemias e linfomas. Conhecer seus mecanismos de ação é fundamental para compreender os aspectos moleculares da carcinogênese. O presente trabalho apresenta uma revisão sobre as características deste gene e sua importância no diagnóstico, prognóstico e terapêutica, o que faz dele um alvo em potencial das estratégias de terapia gênica.
Descritores: Genes p53
-Terapêutica
Terapia Genética
Leucemia
Genoma
Diagnóstico
Carcinogênese
Neoplasias
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM



página 1 de 21 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde